Kelly CRISPR & Gene Editing Technology ETF XDNA
Set alert
7.38 USD +7.38 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 2.58M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.01
- 200-d avg
- 8.43
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 7.01
- 200-day average
- 8.43
About Kelly CRISPR & Gene Editing Technology ETF
The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.
News
- This Week in ETFs: Private Equity Fund Debuts
- 5 Sector ETFs That Beat the Market in November
- This Week in ETFs: ARK & 21Shares on New Crypto Funds
- 5 ETF Areas That Spooked Investors in October
- What Slump? 4 Sector ETFs Up At Least 14% in Q3
- Kelly Debuts With Thematic ETFs
- Kelly ETFs Launches Debut Funds
Your note
Sign in to keep a note on XDNA — it syncs with the Stock Master app.